Concurrent Investment Advisors LLC Purchases New Shares in Moderna, Inc. $MRNA

Concurrent Investment Advisors LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 9,284 shares of the company’s stock, valued at approximately $256,000.

Other institutional investors have also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd purchased a new position in Moderna in the 1st quarter valued at $25,000. TD Private Client Wealth LLC lifted its holdings in Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares in the last quarter. SVB Wealth LLC purchased a new position in Moderna in the 1st quarter valued at $28,000. CX Institutional lifted its holdings in Moderna by 1,129.8% in the 2nd quarter. CX Institutional now owns 1,033 shares of the company’s stock valued at $29,000 after purchasing an additional 949 shares in the last quarter. Finally, Costello Asset Management INC purchased a new position in Moderna in the 1st quarter valued at $30,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Monday. Leerink Partners decreased their price objective on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a report on Friday, August 22nd. Citigroup assumed coverage on Moderna in a report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price objective on the stock. Cowen assumed coverage on Moderna in a report on Sunday, July 13th. They issued a “hold” rating on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $39.93.

Moderna Trading Up 4.7%

Shares of MRNA opened at $27.24 on Tuesday. The firm has a market cap of $10.64 billion, a P/E ratio of -3.62 and a beta of 2.01. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $57.69. The company’s 50-day moving average price is $25.94 and its 200 day moving average price is $27.11.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna’s revenue was down 41.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Equities research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.